MARKET

TROV

TROV

Trovagene
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.660
-0.280
-14.43%
After Hours: 1.730 +0.07 +4.22% 17:59 02/14 EST
OPEN
1.860
PREV CLOSE
1.940
HIGH
1.860
LOW
1.660
VOLUME
907.20K
TURNOVER
--
52 WEEK HIGH
9.65
52 WEEK LOW
0.8800
MARKET CAP
12.85M
P/E (TTM)
-0.4997
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TROV and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

TROV News

  • Trovagene down 10% premarket on mid-stage onvansertib data
  • seekingalpha.4d ago
  • Trovagene down 10% premarket on mid-stage onvansertib data
  • Seeking Alpha - Article.4d ago
  • NTAP, AEG among premarket losers
  • Seeking Alpha - Article.4d ago
  • The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
  • Benzinga.4d ago

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
-0.16%

Hot Stocks

Name
Price
%Change

About TROV

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers. PCM-075 developed high selectivity to PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to other PLK inhibitors. PCM-075 has completed a safety study in patients with advanced metastatic solid tumors with a phase Ib/II clinical trial in patients with AML underway.
More

Webull offers TrovaGene Inc (TROV) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.